Oxford BioDynamics Plc (OXBOF)
USD 0.02
(-86.0%)
USD 0.02
(-86.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 266 Thousand GBP | -5984.48% |
| 2022 | 116 Thousand GBP | 120.83% |
| 2021 | -557 Thousand GBP | -235.54% |
| 2020 | -166 Thousand GBP | -137.81% |
| 2019 | 439 Thousand GBP | -10.95% |
| 2018 | 493 Thousand GBP | -36.47% |
| 2017 | 776 Thousand GBP | 34.96% |
| 2016 | 575 Thousand GBP | 40.93% |
| 2015 | 408 Thousand GBP | 101.98% |
| 2014 | 202 Thousand GBP | 573.33% |
| 2013 | 30 Thousand GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 67 Thousand GBP | 0.0% |
| 2024 Q1 | 67 Thousand GBP | 101.85% |
| 2023 Q2 | -3.2 Million GBP | -4554.17% |
| 2023 Q1 | 72 Thousand GBP | 102.31% |
| 2023 Q4 | -3.61 Million GBP | -6032.79% |
| 2023 Q3 | 61 Thousand GBP | 101.9% |
| 2023 FY | -6.82 Million GBP | -5984.48% |
| 2022 Q3 | 15.5 Thousand GBP | -63.53% |
| 2022 FY | 116 Thousand GBP | 120.83% |
| 2022 Q1 | 42.5 Thousand GBP | -6.59% |
| 2022 Q2 | 42.5 Thousand GBP | 0.0% |
| 2022 Q4 | -3.11 Million GBP | -20170.97% |
| 2021 Q4 | 45.5 Thousand GBP | 0.0% |
| 2021 Q2 | 125 Thousand GBP | 0.0% |
| 2021 Q1 | 125 Thousand GBP | -6.72% |
| 2021 FY | -557 Thousand GBP | -235.54% |
| 2021 Q3 | 45.5 Thousand GBP | -63.6% |
| 2020 FY | -166 Thousand GBP | -137.81% |
| 2020 Q2 | 94 Thousand GBP | 0.0% |
| 2020 Q3 | 134 Thousand GBP | 42.55% |
| 2020 Q1 | 94 Thousand GBP | -43.54% |
| 2020 Q4 | 134 Thousand GBP | 0.0% |
| 2019 FY | 439 Thousand GBP | -10.95% |
| 2019 Q1 | 287 Thousand GBP | -19.5% |
| 2019 Q4 | 166.5 Thousand GBP | 0.0% |
| 2019 Q2 | 287 Thousand GBP | 0.0% |
| 2019 Q3 | 166.5 Thousand GBP | -41.99% |
| 2018 FY | 493 Thousand GBP | -36.47% |
| 2018 Q1 | 236.5 Thousand GBP | -40.8% |
| 2018 Q2 | 236.5 Thousand GBP | 0.0% |
| 2018 Q3 | 356.5 Thousand GBP | 50.74% |
| 2018 Q4 | 356.5 Thousand GBP | 0.0% |
| 2017 Q3 | 399.5 Thousand GBP | 108.07% |
| 2017 FY | 776 Thousand GBP | 34.96% |
| 2017 Q4 | 399.5 Thousand GBP | 0.0% |
| 2017 Q2 | 192 Thousand GBP | 0.0% |
| 2017 Q1 | 192 Thousand GBP | -45.3% |
| 2016 Q1 | 194.5 Thousand GBP | -19.13% |
| 2016 Q2 | 194.5 Thousand GBP | 0.0% |
| 2016 Q4 | 351 Thousand GBP | 0.0% |
| 2016 FY | 575 Thousand GBP | 40.93% |
| 2016 Q3 | 351 Thousand GBP | 80.46% |
| 2015 Q4 | 240.5 Thousand GBP | 0.0% |
| 2015 Q3 | 240.5 Thousand GBP | 117.65% |
| 2015 FY | 408 Thousand GBP | 101.98% |
| 2015 Q1 | 110.5 Thousand GBP | 0.0% |
| 2015 Q2 | 110.5 Thousand GBP | 0.0% |
| 2014 FY | 202 Thousand GBP | 573.33% |
| 2013 FY | 30 Thousand GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | 97.232% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 314.083% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.777% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 183.253% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 98.276% |
| CSL Limited | 7.56 Billion USD | 99.996% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 97.728% |
| Arch Therapeutics, Inc. | -2439.00 USD | 11006.109% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -50.657% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.031% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 651.193% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -89.324% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 98.227% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -8475.113% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 97.284% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -304.698% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 878.917% |
| Mesoblast Limited | -35.16 Million USD | 100.756% |
| Marizyme, Inc. | 457.7 Thousand USD | 41.884% |
| Genus plc | 178.7 Million USD | 99.851% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.879% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -327.474% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 35.148% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 2518.182% |
| ContraFect Corporation | -154 Thousand USD | 272.727% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 632.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -246.53% |
| IMV Inc. | -962.29 Thousand USD | 127.642% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 168.645% |
| MultiCell Technologies, Inc. | 49.32 USD | -539234.955% |
| ONE Bio Corp. | 20.12 Million USD | 98.678% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.339% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -443.967% |
| Q BioMed Inc. | -8988.00 USD | 3059.502% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.059% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1824.585% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.4% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 123.301% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -280.0% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 5471.567% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 372.779% |
| GB Sciences, Inc. | -624.00 USD | 42728.205% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 409.202% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 127984.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -766.224% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 44.863% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.976% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 151.7% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 56.915% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.935% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 3103.613% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 417.237% |
| Kadimastem Ltd | -630.13 Thousand USD | 142.213% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 73.076% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 2347.571% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -50.657% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 80.4% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1017.241% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 40.895% |
| SYBLEU INC | 11.69 Thousand USD | -2174.282% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 94.227% |
| Bioxytran, Inc. | -8285.00 USD | 3310.622% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 171.314% |
| Neutra Corp. | 14.33 Thousand USD | -1755.598% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 424.39% |
| PureTech Health plc | -1.6 Million USD | 116.594% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 126.567% |
| IXICO plc | 3.27 Million USD | 91.865% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 138.329% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 114.852% |
| CSL Limited | 7.7 Billion USD | 99.997% |
| Cellectis S.A. | 18 Thousand USD | -1377.778% |